Glucose Metabolism Disorders: Clinical Trials

24,418 trials for Glucose Metabolism Disorders, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

15724 completed, 3165 unknown, 1885 recruiting, 1163 terminated. 10866 Not applicable, 2361 Phase 2, 2314 Phase 3, 2188 Phase 4, 2091 Phase 1.

By phase and status

PhaseTrialsStatus
Not applicable10866Completed 6815, Unknown 1466, Recruiting 964, Not yet recruiting 471, Terminated 404, Active not recruiting 382, Withdrawn 234, Enrolling by invitation 94, Suspended 36
Phase 22361Completed 1569, Unknown 207, Terminated 206, Recruiting 129, Withdrawn 105, Active not recruiting 73, Not yet recruiting 64, Suspended 5, Enrolling by invitation 3
Phase 32314Completed 1689, Terminated 194, Unknown 176, Recruiting 97, Withdrawn 62, Active not recruiting 47, Not yet recruiting 40, Suspended 6, Enrolling by invitation 3
Phase 42188Completed 1437, Unknown 342, Terminated 153, Recruiting 94, Withdrawn 73, Not yet recruiting 44, Active not recruiting 32, Enrolling by invitation 10, Suspended 3
Phase 12091Completed 1633, Unknown 136, Terminated 111, Recruiting 89, Withdrawn 45, Active not recruiting 40, Not yet recruiting 32, Suspended 5
Early Phase 1223Completed 129, Recruiting 29, Unknown 26, Not yet recruiting 11, Active not recruiting 9, Withdrawn 8, Terminated 6, Enrolling by invitation 4, Suspended 1

Follow Glucose Metabolism Disorders: new trials by email Literature Review of Glucose Metabolism Disorders trials Research Report on Glucose Metabolism Disorders

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Inhibiting GABA Transaminase to Relieve Obesity Induced Hyperinsulinemia and Insulin Resistance
Vigabatrin Pill, Placebo oral tablet - Hyperinsulinism, Insulin Resistance
Phase 2WithdrawnUniversity of Arizona2030-04-152025-07-30
MEDBRIDGE-Guided NCM/CHW Post-Discharge Support for High-Risk T2D Patients
MEDBRIDGE-Guided NCM/CHW Post-Discharge Support Intervention - Type 2 Diabetes, Medication Adherence
Not applicableNot yet recruitingUniversity of Alabama at Birmingham452029-05-012026-05-20
Insul-In This Together: Leveraging Family Support and Diabetes Technology for Adolescents Living With Type 1 Diabetes
Insul-In This Together - Diabetes Type 1
Not applicableNot yet recruitingStanford University2002028-01-012026-10-05
The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction
Caloric Restriction, Hyperglycemic clamp - Type2diabetes
Phase 2Not yet recruitingAdrian Vella202027-12-152026-10-28
Efficacy, Safety, and Treatment Satisfaction of Once-Weekly Tirzepatide in Obese Type 2 Diabetic Patients
Tirzepatide + Standard Therapy (Intervention Group), Standard Oral Antidiabetic Drugs (OADs) - Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Not applicableNot yet recruitingAkhtar Saeed Medical and Dental College522027-12-122026-10-29
PAtient Similarity for Decision-Making in Prevention of Cardiovascular Toxicity (PACT): A Feasibility Study
Clinical Decision Aid, Standard Care - Heart Failure, Coronary Artery Disease
Not yet recruitingMedical College of Wisconsin602027-12-012026-11-03
Role of Endothelial Dysfunction on Exercise Pressor Reflex in Type 2 Diabetes
MitoQ (mitoquinol mesylate), Placebo - Type 2 Diabetes (T2DM), Endothelial Dysfunction
Not applicableNot yet recruitingMedical College of Wisconsin402027-10-012026-10-30
Implementation Support for HEARTS-Based Hypertension and Diabetes Care in Guatemala
HEARTS implementation support, Routine HEARTS implementation - Hypertension (HTN), Type 2 Diabetes
Not applicableNot yet recruitingUniversity of Michigan14402027-10-012026-11-12
Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes Mellitus
Semaglutide (Wegovy) weekly injection - Gestational Diabetes Mellitus (GDM), Metabolic Syndrome
Phase 2 / Phase 3Not yet recruitingUniversity of Massachusetts, Worcester2262027-09-012026-09-28
GLP-1 RA for Stage 1 Type 1 Diabetes
Semaglutide, Placebo - Stage 1 Diabetes Mellitus, Type 1
Phase 2Not yet recruitingChildren's Hospital Medical Center, Cincinnati152027-09-012026-02-24
South Asians With Type 2 Diabetes at Risk for Depression
CHW-led T2D Intervention - Type 2 Diabetes
Not applicableNot yet recruitingNYU Langone Health1002027-08-012026-05-19
Community Health Worker Nutrition Self-Management Support for Cardio-Kidney-Metabolic Health
INTEGRATE-CHW, Usual Care - Hypertension (HTN), CKD - Chronic Kidney Disease
Not applicableNot yet recruitingFlorida International University2002027-07-152026-11-05
cfMSC Therapy for Diabetes
cfMSC therapy for diabetes - Type II Diabetes Mellitus
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute302027-06-302026-11-02
Na-Phenylbutyrate VAscular Trial
Sodium Phenylbutyrate, Placebo - Diabetes
Early Phase 1Not yet recruitingUniversity of Pennsylvania302027-06-012026-07-28
A Study to Lower Blood Pressure One Year After Childbirth in Women Who Had Preeclampsia
The intervention in the GESTA-SCORE study involves providing detailed feedback from vascular imaging to women who have experienced adverse pregnancy outcomes (APOs). - Adverse Pregnancy Outcomes, Cardiovascular Diseases
Not applicableNot yet recruitingMaternal-Infantil Vall d´Hebron Hospital1502027-06-012026-11-03
The Prevalence of Hyperglycemia in Surgical Patients With Pre-diabetes
Prediabetes or Diabetes, Surgery Complications
Not yet recruitingUniversity of Calgary7502027-05-012026-06-23
Trial of CGM Technology in Persons Living With Prediabetes
Stelo CGM - Prediabetes
Not applicableNot yet recruitingWake Forest University Health Sciences1002027-04-012026-10-23
Better Care Closer to Home: Enhancing Primary and Community Care
Path Active™, a smart insole system designed to reduce the risk of plantar ulceration in patients with diabetic foot disease - Diabetic Foot Disease, Recurrence
Not applicableNot yet recruitingUniversidad Complutense de Madrid842027-04-012026-11-03
CKM For Safe Use of SGLT2i in Type 1 Diabetes
Sotagliflozin Low Dose, Sotagliflozin High Dose, Dual Continuous Glucose and Ketone Monitor - Type 1 Diabetes (T1D)
Phase 3Not yet recruitingUniversity of California, San Diego522027-04-012026-11-04
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
ESG with OverStitch - Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Not applicableNot yet recruitingBoston Scientific Corporation502027-04-012026-11-06

Showing 20 of 24418. Sign in to see all of them.

Narrower conditions

Diabetes Mellitus, Type 2 (10071)  ·  Diabetes Mellitus (8232)  ·  Diabetes Mellitus, Type 1 (3574)  ·  Insulin Resistance (2967)  ·  Obesity (2782)  ·  Metabolic Syndrome (2099)  ·  Hypertension (1276)  ·  Prediabetic State (918)  ·  Cardiovascular Diseases (910)  ·  Motor Activity (869)  ·  Diabetes, Gestational (831)  ·  Glucose Intolerance (787)  ·  Overweight (779)  ·  Hyperglycemia (769)  ·  Hypoglycemia (664)

Broader conditions

Nutritional and Metabolic Diseases (24393)  ·  Metabolic Diseases (24125)  ·  Endocrine System Diseases (20351)  ·  Diabetes Mellitus (12022)  ·  Pathological Conditions, Signs and Symptoms (5515)  ·  Hyperinsulinism (4721)  ·  Signs and Symptoms (4013)  ·  Immune System Diseases (3843)  ·  Autoimmune Diseases (3581)  ·  Body Weight (3232)  ·  Nutrition Disorders (3227)  ·  Overnutrition (3128)  ·  Vascular Diseases (2578)  ·  Cardiovascular Diseases (2574)

Interventions

Metformin (1028)  ·  Insulin Glargine (540)  ·  Exercise (487)  ·  Insulin (451)  ·  Sitagliptin Phosphate (403)  ·  Insulin Aspart (327)  ·  semaglutide (305)  ·  dapagliflozin (304)  ·  Pioglitazone (293)  ·  Liraglutide (278)  ·  empagliflozin (260)  ·  Insulin Lispro (218)  ·  Continuous Glucose Monitoring (217)  ·  Insulin Detemir (195)  ·  glimepiride (189)

Sponsors

Novo Nordisk A/S (855)  ·  AstraZeneca (387)  ·  Eli Lilly and Company (315)  ·  Sanofi (273)  ·  Merck Sharp & Dohme LLC (194)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (166)  ·  GlaxoSmithKline (150)  ·  University of Aarhus (147)  ·  University of Colorado, Denver (145)  ·  Boehringer Ingelheim (139)  ·  Takeda (123)  ·  Mayo Clinic (119)  ·  Brigham and Women's Hospital (116)  ·  Yale University (112)  ·  Massachusetts General Hospital (110)

Countries

United States (8332)  ·  Canada (1555)  ·  China (1492)  ·  Germany (1394)  ·  United Kingdom (1233)  ·  Denmark (1013)  ·  France (1007)  ·  Italy (895)  ·  Spain (844)  ·  South Korea (773)  ·  Turkey (Türkiye) (694)  ·  Netherlands (639)  ·  Mexico (627)  ·  Brazil (548)  ·  Sweden (533)

Top investigators

Guillermo Umpierrez, MD (29)

Results publications

PMID 38770818, PMID 39963952, PMID 33166419, PMID 22236356, PMID 25387217, PMID 38682786, PMID 25504028, PMID 35472672, PMID 31903692, PMID 32998732, PMID 32501595, PMID 37526194, PMID 35044568, PMID 39171639, PMID 22913891, PMID 31606880, PMID 32803882, PMID 34213819, PMID 23010561, PMID 26894924, PMID 32267058, PMID 33210751, PMID 33512717, PMID 39735417, PMID 26580237, PMID 27402391, PMID 36542287, PMID 37435938, PMID 24517339, PMID 32306296, PMID 33327727, PMID 38837240, PMID 21450987, PMID 21883806, PMID 22193143, PMID 22234149, PMID 22862847, PMID 23130654, PMID 23186975, PMID 24170235, PMID 24786834, PMID 26232910, PMID 27977934, PMID 30615985, PMID 30880443, PMID 31769496, PMID 31797522, PMID 32324065, PMID 32324082, PMID 32372382

NIH funding

2009 (82), 2015 (73), 2014 (70), 2017 (67), 2008 (62), 2019 (61), 2016 (53), 2018 (53), 2023 (50), 2025 (49), 2005 (37), OT2HL158287 (10), P30DK111024 (10), 2004 (9), P50MD017338 (8)